- Home
- CIFR vs ADPT Comparison
CIFR vs ADPT Comparison
Compare CIFR & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIFR
- ADPT
- Stock Information
- Founded
- CIFR 2021
- ADPT 2009
- Country
- CIFR United States
- ADPT United States
- Employees
- CIFR N/A
- ADPT N/A
- Industry
- CIFR Investment Bankers/Brokers/Service
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CIFR Finance
- ADPT Health Care
- Exchange
- CIFR Nasdaq
- ADPT Nasdaq
- Market Cap
- CIFR 1.2B
- ADPT 1.4B
- IPO Year
- CIFR N/A
- ADPT 2019
- Fundamental
- Price
- CIFR $3.79
- ADPT $10.38
- Analyst Decision
- CIFR Strong Buy
- ADPT Strong Buy
- Analyst Count
- CIFR 10
- ADPT 7
- Target Price
- CIFR $7.58
- ADPT $10.57
- AVG Volume (30 Days)
- CIFR 23.3M
- ADPT 1.3M
- Earning Date
- CIFR 08-12-2025
- ADPT 07-31-2025
- Dividend Yield
- CIFR N/A
- ADPT N/A
- EPS Growth
- CIFR N/A
- ADPT N/A
- EPS
- CIFR N/A
- ADPT N/A
- Revenue
- CIFR $152,092,000.00
- ADPT $189,527,000.00
- Revenue This Year
- CIFR $88.07
- ADPT $24.46
- Revenue Next Year
- CIFR $68.21
- ADPT $20.25
- P/E Ratio
- CIFR N/A
- ADPT N/A
- Revenue Growth
- CIFR N/A
- ADPT 8.61
- 52 Week Low
- CIFR $1.86
- ADPT $2.99
- 52 Week High
- CIFR $7.99
- ADPT $10.87
- Technical
- Relative Strength Index (RSI)
- CIFR 54.27
- ADPT 62.28
- Support Level
- CIFR $3.63
- ADPT $9.90
- Resistance Level
- CIFR $3.98
- ADPT $10.85
- Average True Range (ATR)
- CIFR 0.30
- ADPT 0.48
- MACD
- CIFR -0.02
- ADPT -0.02
- Stochastic Oscillator
- CIFR 62.28
- ADPT 68.39
About CIFR Cipher Mining Inc.
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).